Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

(2018) Peter Connick et al.   BMJ Open

Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine

(2017) Roopa Bhat et al.   JOURNAL OF NEUROIMMUNOLOGY

Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework

(2016) Saurabh Jain et al.   Frontiers in Neuroscience

Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial

(2014) Melissa Cambron et al.   Trials

Will the real multiple sclerosis please stand up?

(2012) Peter K. Stys et al.   NATURE REVIEWS NEUROSCIENCE

Fluoxetine Promotes Remission in Acute Experimental Autoimmune Encephalomyelitis in Rats

(2012) Xi-qiu Yuan et al.   NEUROIMMUNOMODULATION

Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes

(2011) Igor Allaman et al.   PSYCHOPHARMACOLOGY

The search for responsive clinical endpoints in primary progressive multiple sclerosis

(2009) LVAE Bosma et al.   Multiple Sclerosis Journal

Therapeutic Potential of Fluoxetine in Neurological Disorders

(2008) Jop P. Mostert et al.   CNS Neuroscience & Therapeutics

Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study

(2008) J P Mostert et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY